triiodothyronine has been researched along with Heart Failure, Systolic in 2 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Heart Failure, Systolic: Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There were no side-effects in terms of cardiac arrhythmias and no change in resting heart rate." | 6.80 | Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study. ( Andersen, U; Dominguez, H; Faber, J; Holmager, P; Kistorp, C; Mark, P; Nygaard, B; Raymond, I; Schmidt, U; Zerahn, B, 2015) |
| "There were no side-effects in terms of cardiac arrhythmias and no change in resting heart rate." | 2.80 | Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study. ( Andersen, U; Dominguez, H; Faber, J; Holmager, P; Kistorp, C; Mark, P; Nygaard, B; Raymond, I; Schmidt, U; Zerahn, B, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holmager, P | 1 |
| Schmidt, U | 1 |
| Mark, P | 1 |
| Andersen, U | 1 |
| Dominguez, H | 1 |
| Raymond, I | 1 |
| Zerahn, B | 1 |
| Nygaard, B | 1 |
| Kistorp, C | 1 |
| Faber, J | 1 |
| Passino, C | 1 |
| Pingitore, A | 1 |
| Landi, P | 1 |
| Fontana, M | 1 |
| Zyw, L | 1 |
| Clerico, A | 1 |
| Emdin, M | 1 |
| Iervasi, G | 1 |
1 trial available for triiodothyronine and Heart Failure, Systolic
| Article | Year |
|---|---|
Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Double-Blind Method; Female; Heart Failure, Systolic; | 2015 |
1 other study available for triiodothyronine and Heart Failure, Systolic
| Article | Year |
|---|---|
Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure.
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Male; Middle Aged; Mul | 2009 |